Overview

Atacicept in Subjects With Optic Neuritis

Status:
Terminated

Trial end date:
2011-01-01

Target enrollment:

Participant gender:

Summary

This study was intended to evaluate the efficacy, safety and tolerability of atacicept compared to placebo and to explore the neuroprotective effect of atacicept as assessed by OCT in subjects with ON as CIS. The study was randomized. Study medication was administered via subcutaneous (under the skin) injections.

Phase:

Phase 2

Details

Lead Sponsor:

EMD Serono

Collaborators:

Merck KGaA
Merck KGaA, Darmstadt, Germany